Response to Office Action

TRULANCE

BAUSCH HEALTH IRELAND LIMITED

Response to Office Action

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011)
OMB No. 0651-0050 (Exp 07/31/2017)

Response to Office Action


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 87392678
LAW OFFICE ASSIGNED LAW OFFICE 106
MARK SECTION
MARK FILE NAME http://uspto.report/TM/87392678/mark.png
LITERAL ELEMENT TRULANCE
STANDARD CHARACTERS NO
USPTO-GENERATED IMAGE NO
GOODS AND/OR SERVICES SECTION (current)
INTERNATIONAL CLASS 005
DESCRIPTION
Pharmaceutical preparations; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and diseases; gastrointestinal hormone analogue preparations for medical purposes; laxatives; antiemetics; anti-diarrheal and anti-inflammatory pharmaceutical preparations; all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetes
        FIRST USE ANYWHERE DATE At least as early as 03/00/2017
        FIRST USE IN COMMERCE DATE At least as early as 03/00/2017
FILING BASIS Section 1(b)
FILING BASIS Section 44(d)
        FOREIGN APPLICATION NUMBER 52243
       FOREIGN APPLICATION COUNTRY Trinidad and Tobago
        FOREIGN FILING DATE 12/22/2016
GOODS AND/OR SERVICES SECTION (proposed)
INTERNATIONAL CLASS 005
TRACKED TEXT DESCRIPTION
Pharmaceutical preparations; pharmaceutical preparations for the treatment of gastrointestinal swelling, bloating, pain, inflammation, and diarrhea; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and diseases; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and gastrointestinal diseases; gastrointestinal hormone analogue preparations for medical purposes; laxatives; antiemetics; anti-diarrheal and anti-inflammatory pharmaceutical preparations; anti-diarrheal and anti-inflammatory pharmaceutical preparations all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetes; all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetes
FINAL DESCRIPTION
pharmaceutical preparations for the treatment of gastrointestinal swelling, bloating, pain, inflammation, and diarrhea; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and gastrointestinal diseases; gastrointestinal hormone analogue preparations for medical purposes; laxatives; antiemetics; anti-diarrheal and anti-inflammatory pharmaceutical preparations all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetes
       FIRST USE ANYWHERE DATE At least as early as 03/00/2017
       FIRST USE IN COMMERCE DATE At least as early as 03/00/2017
FILING BASIS Section 1(b)
FILING BASIS Section 44(d)
       FOREIGN APPLICATION NUMBER 52243
       FOREIGN APPLICATION COUNTRY Trinidad and Tobago
       FOREIGN FILING DATE 12/22/2016
       INTENT TO
       PERFECT 44(d)
At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.
SIGNATURE SECTION
RESPONSE SIGNATURE /kkw/
SIGNATORY'S NAME Karen K. Won
SIGNATORY'S POSITION Attorney of record, New York bar member
SIGNATORY'S PHONE NUMBER 212 479 6467
DATE SIGNED 06/23/2017
AUTHORIZED SIGNATORY YES
FILING INFORMATION SECTION
SUBMIT DATE Wed Jun 28 00:46:29 EDT 2017
TEAS STAMP USPTO/ROA-XXX.XXX.XXX.XX-
20170628004629182826-8739
2678-5907ffcb3f2a73e920b4
b8aa5894be3213ef6d8e48169
aa4957f6e998ac214dd7f-N/A
-N/A-20170623144455142670



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011)
OMB No. 0651-0050 (Exp 07/31/2017)

Response to Office Action


To the Commissioner for Trademarks:

Application serial no. 87392678 TRULANCE (Stylized and/or with Design, see http://uspto.report/TM/87392678/mark.png) has been amended as follows:

CLASSIFICATION AND LISTING OF GOODS/SERVICES
Applicant proposes to amend the following class of goods/services in the application:
Current: Class 005 for Pharmaceutical preparations; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and diseases; gastrointestinal hormone analogue preparations for medical purposes; laxatives; antiemetics; anti-diarrheal and anti-inflammatory pharmaceutical preparations; all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetes
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.

In International Class 005, the mark was first used at least as early as 03/00/2017 and first used in commerce at least as early as 03/00/2017 .

Filing Basis: Section 44(d), Priority based on foreign filing: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services, and asserts a claim of priority based upon a foreign application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization, and asserts a claim of priority based upon a foreign application. For a certification application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods or services that meet the certification standards of the applicant, and the applicant asserts a claim of priority based upon a foreign application. Claim of priority is based on[ Trinidad and Tobago application number 52243 filed 12/22/2016]. 15 U.S.C.Section 1126(d), as amended.

Proposed:
Tracked Text Description: Pharmaceutical preparations; pharmaceutical preparations for the treatment of gastrointestinal swelling, bloating, pain, inflammation, and diarrhea; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and diseases; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and gastrointestinal diseases; gastrointestinal hormone analogue preparations for medical purposes; laxatives; antiemetics; anti-diarrheal and anti-inflammatory pharmaceutical preparations; anti-diarrheal and anti-inflammatory pharmaceutical preparations all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetes; all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetesClass 005 for pharmaceutical preparations for the treatment of gastrointestinal swelling, bloating, pain, inflammation, and diarrhea; pharmaceutical preparations for use in the treatment of constipation, irritable bowel syndrome, colitis, gastrointestinal disorders and gastrointestinal diseases; gastrointestinal hormone analogue preparations for medical purposes; laxatives; antiemetics; anti-diarrheal and anti-inflammatory pharmaceutical preparations all of the aforesaid excluding pharmaceutical preparations for the treatment of diabetes
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.

In International Class 005, the mark was first used at least as early as 03/00/2017 . and first used in commerce at least as early as 03/00/2017 .

Filing Basis: Section 44(d), Priority based on foreign filing:For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services, and asserts a claim of priority based upon a foreign application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization, and asserts a claim of priority based upon a foreign application. For a certification mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods or services that meet the certification standards of the applicant, and the applicant asserts a claim of priority based upon a foreign application. Claim of priority is based on [ Trinidad and Tobago application number 52243 filed 12/22/2016]. 15 U.S.C.Section 1126(d), as amended.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration. If ultimately the applicant does not rely on Section 44(e) as a basis for registration, a valid claim of priority may be retained.

SIGNATURE(S)
Response Signature
Signature: /kkw/     Date: 06/23/2017
Signatory's Name: Karen K. Won
Signatory's Position: Attorney of record, New York bar member

Signatory's Phone Number: 212 479 6467

The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of the highest court of a U.S. state, which includes the District of Columbia, Puerto Rico, and other federal territories and possessions; and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S. attorney or a Canadian attorney/agent not currently associated with his/her company/firm previously represented the owner/holder in this matter: (1) the owner/holder has filed or is concurrently filing a signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of the prior representative to withdraw; (3) the owner/holder has filed a power of attorney appointing him/her in this matter; or (4) the owner's/holder's appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing him/her as an associate attorney in this matter.

        
Serial Number: 87392678
Internet Transmission Date: Wed Jun 28 00:46:29 EDT 2017
TEAS Stamp: USPTO/ROA-XXX.XXX.XXX.XX-201706280046291
82826-87392678-5907ffcb3f2a73e920b4b8aa5
894be3213ef6d8e48169aa4957f6e998ac214dd7
f-N/A-N/A-20170623144455142670



uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed